Download PDF
Hamostaseologie 2020; 40(02): 184-200
DOI: 10.1055/a-1113-0655
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature

Thomas Moner-Banet
1   Department of Internal Medicine, Riviera-Chablais Hospital, Rennaz, Switzerland
,
Lorenzo Alberio
2   Division of Haematology and Central Haematology Laboratory, CHUV Lausanne University Hospital, University of Lausanne (UNIL), Lausanne, Switzerland
,
Pierre-Alexandre Bart
3   Department of Internal Medicine, CHUV Lausanne University Hospital, University of Lausanne (UNIL), Lausanne, Switzerland
› Author Affiliations
Further Information

Publication History

20 October 2019

06 February 2020

Publication Date:
26 May 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC) laboratory monitoring. The aims of the present review were to evaluate published data on monitoring DOACs, to provide clinical guidance on how to interpret results, and to summarize why, when, and how to monitor DOACs.

Methods The publications screened for this review were obtained through a PubMed search for articles published in English or French before April 2019 that had the following as their main themes: DOAC monitoring, DOAC exposure–effect relationship, DOAC drug interactions, and pharmacokinetics and pharmacodynamics of DOACs.

Results DOACs show important inter- and intrapersonal concentration variability and a significant exposure–effect relationship. Concentrations out of the expected range have been shown to lead to an increased adverse event rate and a lower efficacy. No definitive therapeutic range exists for DOACs except for dabigatran for which trough levels of 40 to 200 ng/mL seem to be the consensus. Indications to monitor include suspected drug accumulation in special patient populations, suspected drug failure, and acute situations such as hemorrhagic or thrombotic events.

Conclusion There is a likely benefit to monitor DOACs in order to improve their safety and efficacy but randomized controlled trials are required to determine the therapeutic range of these drugs and evaluate whether DOAC monitoring can improve outcomes in a clinical setting.

Keywords

direct oral anticoagulant - monitoring - dose tailoring - plasma level
 

  • References

  • 1 Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 2010; 8 (04) 621-626
    CrossrefPubMedGoogle Scholar
  • 2 Connolly SJ, Ezekowitz MD, Yusuf S. , et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 3 Giugliano RP, Ruff CT, Braunwald E. , et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 4 Patel MR, Mahaffey KW, Garg J. , et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 5 Granger CB, Alexander JH, McMurray JJV. , et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 6 Reilly PA, Lehr T, Haertter S. , et al. RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
    CrossrefPubMedGoogle Scholar
  • 7 Powell JR. Are new oral anticoagulant dosing recommendations optimal for all patients?. JAMA 2015; 313 (10) 1013-1014
    CrossrefPubMedGoogle Scholar
  • 8 Paré G, Eriksson N, Lehr T. , et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127 (13) 1404-1412
    CrossrefPubMedGoogle Scholar
  • 9 Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014; 349: g4670
    PubMedGoogle Scholar
  • 10 An idea for a mid to long term strategy for Pradaxa [Internet]. Boehringer Ingelheim International. Available at: https://www.bmj.com/investigation/dabigatran . Accessed February 26, 2019
    PubMedGoogle Scholar
  • 11 Safouris A, Triantafyllou N, Parissis J, Tsivgoulis G. The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio. Ther Adv Neurol Disorder 2015; 8 (06) 245-254
    PubMedGoogle Scholar
  • 12 FDA. Pradaxa clinical pharmacology and biopharmaceutics review(s) [Internet]. 2011 [cited 2019 Feb 25]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf . Accessed February 25, 2019
    PubMedGoogle Scholar
  • 13 Infromation professionnelle du Compendium Suisse des Médicaments: Pradaxa [Internet]. Compendium Suisse des Médicaments. Available at: https://compendium.ch/mpro/mnr/23436/html/fr . Accessed March 5, 2019
    PubMedGoogle Scholar
  • 14 Šinigoj P, Malmström RE, Vene N. , et al. Dabigatran concentration: variability and potential bleeding prediction in “real-life” patients with atrial fibrillation. Basic Clin Pharmacol Toxicol 2015; 117 (05) 323-329
    CrossrefPubMedGoogle Scholar
  • 15 Albaladejo P, Samama C-M, Sié P. , et al. GIHP-NACO Study Group. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology 2017; 127 (01) 111-120
    CrossrefPubMedGoogle Scholar
  • 16 Volbers B, Köhrmann M, Kallmünzer B. , et al. Dabigatran plasma levels in acute cerebrovascular events. J Stroke Cerebrovasc Dis 2016; 25 (04) 877-882
    CrossrefPubMedGoogle Scholar
  • 17 Eriksson BI, Dahl OE, Büller HR. , et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3 (01) 103-111
    CrossrefPubMedGoogle Scholar
  • 18 Testa S, Paoletti O, Legnani C. , et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018; 16 (05) 842-848
    CrossrefPubMedGoogle Scholar
  • 19 Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78 (03) 599-609
    CrossrefPubMedGoogle Scholar
  • 20 Chaussade E, Hanon O, Boully C. , et al. Real-life peak and trough dabigatran plasma measurements over time in hospitalized geriatric patients with atrial fibrillation. J Nutr Health Aging 2018; 22 (01) 165-173
    CrossrefPubMedGoogle Scholar
  • 21 Schellings MW, Boonen K, Schmitz EM. , et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res 2016; 139: 128-134
    CrossrefPubMedGoogle Scholar
  • 22 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 23 FDA. Xarelto – clinical pharmacology & biopharmaceutical review [Internet]. FDA; 2009. . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf . Accessed February 25, 2019
    Google Scholar
  • 24 Girgis IG, Patel MR, Peters GR. , et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol 2014; 54 (08) 917-927
    CrossrefPubMedGoogle Scholar
  • 25 Gulilat M, Tang A, Gryn SE. , et al. Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care. Can J Cardiol 2017; 33 (08) 1036-1043
    CrossrefPubMedGoogle Scholar
  • 26 Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med 2019; 9 (01) E7
    CrossrefPubMedGoogle Scholar
  • 27 Kubitza D, Berkowitz SD, Misselwitz F. Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications. Clin Appl Thromb Hemost 2016; 22 (05) 412-422
    CrossrefPubMedGoogle Scholar
  • 28 Nakano Y, Kondo T, Osanai H. , et al. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. J Cardiol 2015; 65 (03) 185-190
    PubMedGoogle Scholar
  • 29 Woodruff AE, Wovkulich MM, Mogle BT, Hassan AK. Association between prothrombin time and bleeding in hospitalized patients receiving rivaroxaban. Am J Health Syst Pharm 2018; 75 (22) 1783-1789
    CrossrefPubMedGoogle Scholar
  • 30 Sakaguchi T, Osanai H, Murase Y. , et al. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol 2017; 70 (03) 244-249
    PubMedGoogle Scholar
  • 31 Wada S, Toyoda K, Sato S. , et al. Anti-Xa activity and event risk in patients with direct factor Xa inhibitors initiated early after stroke. Circ J 2018; 82 (11) 2872-2879
    CrossrefPubMedGoogle Scholar
  • 32 Krause M, Henningsen A, Torge A. , et al. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. Thromb Res 2016; 148: 145-151
    CrossrefPubMedGoogle Scholar
  • 33 Seiffge DJ, Kägi G, Michel P. , et al. Novel Oral Anticoagulants in Stroke Patients study group. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Ann Neurol 2018; 83 (03) 451-459
    CrossrefPubMedGoogle Scholar
  • 34 Zalewski J, Rychlak R, Góralczyk T, Undas A. Rivaroxaban concentration in patients with deep vein thrombosis who reported thrombus progression or minor hemorrhagic complications: first Polish experience. Pol Arch Med Wewn 2014; 124 (10) 553-555
    PubMedGoogle Scholar
  • 35 Romano SL, Chiarugi P, Casini M, Pellegrini G, Ruocco L. A low rivaroxaban plasma level may indicate anticoagulation undertreatment. Eur J Case Rep Intern Med 2018; 5 (11) 000937
    PubMedGoogle Scholar
  • 36 Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol 2016; 7: 494
    PubMedGoogle Scholar
  • 37 Barton J, Wong A, Graudins A. Anti-Xa activity in apixaban overdose: a case report. Clin Toxicol (Phila) 2016; 54 (09) 871-873
    CrossrefPubMedGoogle Scholar
  • 38 Repplinger DJ, Hoffman RS, Nelson LS, Hines EQ, Howland M, Su MK. Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations. Clin Toxicol (Phila) 2016; 54 (08) 647-649
    CrossrefPubMedGoogle Scholar
  • 39 Spiller HA, Mowry JB, Aleguas Jr A. , et al. An observational study of the factor Xa inhibitors rivaroxaban and apixaban as reported to eight poison centers. Ann Emerg Med 2016; 67 (02) 189-195
    CrossrefPubMedGoogle Scholar
  • 40 Becker RC, Alexander JH, Newby LK. , et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 2010; 104 (05) 976-983
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Frost C, Wang J, Nepal S. , et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75 (02) 476-487
    CrossrefPubMedGoogle Scholar
  • 42 Eliquis: Summary of product characteristics [Internet]. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf . Accessed March 4, 2019
    PubMedGoogle Scholar
  • 43 Ueshima S, Hira D, Fujii R. , et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics 2017; 27 (09) 329-336
    CrossrefPubMedGoogle Scholar
  • 44 FDA. Apixaban clinical pharmacology/biopharmaceutics review [Internet]. FDA; 2012. . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf . Accessed February 25, 2019
    Google Scholar
  • 45 Bhagirath VC, Eikelboom JW, Hirsh J. , et al. Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open 2017; 1 (02) e139-e145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Byon W, Sweeney K, Frost C, Boyd RA. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacometrics Syst Pharmacol 2017; 6 (05) 340-349
    CrossrefPubMedGoogle Scholar
  • 47 Testa S, Dellanoce C, Paoletti O. , et al. Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. Thromb Res 2019; 175: 61-67
    CrossrefPubMedGoogle Scholar
  • 48 FDA. Edoxaban clinical pharmacology and biopharmaceutics review [Internet]. FDA; 2014 . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf . Accessed February 25, 2019
    PubMedGoogle Scholar
  • 49 Weitz JI, Connolly SJ, Patel I. , et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104 (03) 633-641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Giugliano RP. Compilation of oral presentations: OC-WE-003 The relationship between oral factor Xa (FXa) inhibitor du-176b pharmacokinetics (PK) and the probability of bleeding events (BE) in patients with atrial fibrillation (AF). Boston, MA: International Society on Thrombosis and Haemostasis; 2009
    Google Scholar
  • 51 Salazar DE, Mendell J, Kastrissios H. , et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107 (05) 925-936
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Ruff CT, Giugliano RP, Braunwald E. , et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385 (9984): 2288-2295
    CrossrefPubMedGoogle Scholar
  • 53 Yin OQP, Antman EM, Braunwald E. , et al. Linking endogenous factor Xa activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 trial. Circulation 2018; 138 (18) 1963-1973
    CrossrefPubMedGoogle Scholar
  • 54 Chao T-F, Chen S-A, Ruff CT. , et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40 (19) 1518-1527
    CrossrefPubMedGoogle Scholar
  • 55 Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy 2017; 37 (02) 236-248
    CrossrefPubMedGoogle Scholar
  • 56 Tamigniau A, Douxfils J, Nicolas J-B. , et al. Why, when and how to monitor new oral anticoagulants [in French]. Rev Med Suisse 2014; 10 (416) 326-333
    PubMedGoogle Scholar
  • 57 Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol 2018; 9: 1220
    CrossrefPubMedGoogle Scholar
  • 58 Gupta M, Singh N, Tsigoulis M. , et al. Underuse of full dose factor Xa inhibition in atrial fibrillation: insight from the SPRINT-AF registry. J Am Coll Cardiol 2015; 65 (10) A348
    CrossrefPubMedGoogle Scholar
  • 59 Wehbe RM, Yadlapati A. Underuse of oral anticoagulants for nonvalvular atrial fibrillation: past, present, and future. Tex Heart Inst J 2016; 43 (04) 287-290
    PubMedGoogle Scholar
  • 60 Avorn J. The psychology of clinical decision making - implications for medication use. N Engl J Med 2018; 378 (08) 689-691
    CrossrefPubMedGoogle Scholar
  • 61 Dillinger J-G, Aleil B, Cheggour S. , et al. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: why we should not underdose our patients. Arch Cardiovasc Dis 2018; 111 (02) 85-94
    CrossrefPubMedGoogle Scholar
  • 62 Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation. Ann Pharmacother 2018; 52 (02) 147-153
    CrossrefPubMedGoogle Scholar
  • 63 Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis 2017; 11 (09) 243-256
    CrossrefPubMedGoogle Scholar
  • 64 Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis 2017; 10: 135-143
    CrossrefPubMedGoogle Scholar
  • 65 Barrios V, Górriz JL. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. J Comp Eff Res 2015; 4 (06) 651-664
    CrossrefPubMedGoogle Scholar
  • 66 Andò G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis. Int J Cardiol 2017; 231: 162-169
    CrossrefPubMedGoogle Scholar
  • 67 Feldberg J, Patel P, Farrell A. , et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant 2019; 34 (02) 265-277
    CrossrefPubMedGoogle Scholar
  • 68 Greenblatt DJ, Patel M, Harmatz JS, Nicholson WT, Rubino CM, Chow CR. Impaired rivaroxaban clearance in mild renal insufficiency with verapamil coadministration: potential implications for bleeding risk and dose selection. J Clin Pharmacol 2018; 58 (04) 533-540
    CrossrefPubMedGoogle Scholar
  • 69 Becattini C, Giustozzi M, Ranalli MG. , et al. Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation. J Thromb Haemost 2018; 16 (05) 833-841
    CrossrefPubMedGoogle Scholar
  • 70 Min M, Sibicky S. Concerns for bleeding in the elderly with the use of direct oral anticoagulants. Consult Pharm 2018; 33 (05) 262-267
    CrossrefPubMedGoogle Scholar
  • 71 Ruff CT, Giugliano RP, Braunwald E. , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 72 Eikelboom JW, Wallentin L, Connolly SJ. , et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123 (21) 2363-2372
    CrossrefPubMedGoogle Scholar
  • 73 Kailas SD, Thambuluru SR. Efficacy and safety of direct oral anticoagulants compared to warfarin in prevention of thromboembolic events among elderly patients with atrial fibrillation. Cureus 2016; 8 (10) e836
    PubMedGoogle Scholar
  • 74 Bando S, Nishikado A, Hiura N. , et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol 2018; 71 (02) 197-201
    PubMedGoogle Scholar
  • 75 Nissan R, Spectre G, Hershkovitz A. , et al. Apixaban levels in octogenarian patients with non-valvular atrial fibrillation. Drugs Aging 2019; 36 (02) 165-177
    CrossrefPubMedGoogle Scholar
  • 76 Khan F, Huang H, Datta YH. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis 2016; 42 (04) 573-578
    CrossrefPubMedGoogle Scholar
  • 77 Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. ; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
    CrossrefPubMedGoogle Scholar
  • 78 Albaladejo P, Pernod G, Godier A. , et al. Members of the French Working Group on Perioperative Haemostasis. Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016. Anaesth Crit Care Pain Med 2018; 37 (04) 391-399
    PubMedGoogle Scholar
  • 79 Steffel J, Verhamme P, Potpara TS. , et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 80 Kaatz S, Mahan CE, Nakhle A. , et al. Management of elective surgery and emergent bleeding with direct oral anticoagulants. Curr Cardiol Rep 2017; 19 (12) 124
    CrossrefPubMedGoogle Scholar
  • 81 Prisco D, Ageno W, Becattini C. , et al. SIMI (Italian Society of Internal Medicine); FADOI (Federation of Associations of Hospital Doctors on Internal Medicine); SISET (Italian Society for the Study of Haemostasis and Thrombosis). Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 2017; 12 (03) 387-406
    CrossrefPubMedGoogle Scholar
  • 82 Douketis JD, Spyropoulos AC, Anderson JM. , et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost 2017; 117 (12) 2415-2424
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Godier A, Dincq A-S, Martin A-C. , et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38 (31) 2431-2439
    CrossrefPubMedGoogle Scholar
  • 84 Pernod G, Albaladejo P, Godier A. , et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013 [in French]. Ann Fr Anesth Reanim 2013; 32 (10) 691-700
    CrossrefPubMedGoogle Scholar
  • 85 Bertaggia-Calderara D, Kröll D, Gerschheimer C. , et al. Effect of rivaroxaban on thrombin generation in vivo. A study in obese patients. Int J Lab Hematol 2018; 40 (01) e11-e14
    CrossrefPubMedGoogle Scholar
  • 86 Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013; 52 (04) 243-254
    CrossrefPubMedGoogle Scholar
  • 87 Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: a systematic review. Thromb Res 2018; 170: 102-108
    CrossrefPubMedGoogle Scholar
  • 88 Ha NB, Regal RE. Anticoagulation in patients with cirrhosis: caught between a rock-liver and a hard place. Ann Pharmacother 2016; 50 (05) 402-409
    CrossrefPubMedGoogle Scholar
  • 89 Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis. Int J Hepatol 2018; 2018: 8432781
    PubMedGoogle Scholar
  • 90 Chang SH, Chou IJ, Yeh YH. , et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318 (13) 1250-1259
    CrossrefPubMedGoogle Scholar
  • 91 Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011; 155 (02) 137-149
    CrossrefPubMedGoogle Scholar
  • 92 Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47 (02) 218-226
    CrossrefPubMedGoogle Scholar
  • 93 Upreti VV, Wang J, Barrett YC. , et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013; 76 (06) 908-916
    CrossrefPubMedGoogle Scholar
  • 94 Di Minno MND, Lupoli R, Di Minno A, Ambrosino P, Scalera A, Dentali F. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials. Ann Med 2015; 47 (01) 61-68
    CrossrefPubMedGoogle Scholar
  • 95 Boonyawat K, Caron F, Li A. , et al. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost 2017; 15 (07) 1322-1333
    CrossrefPubMedGoogle Scholar
  • 96 Pradaxa: summary of product characteristics [Internet]. European Medicines Agency; Available at: https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_en.pdf . Accessed March 9, 2020
    PubMedGoogle Scholar
  • 97 Safouris A, Demulder A, Triantafyllou N, Tsivgoulis G. Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. J Neurol Sci 2014; 346 (1–2): 366-367
    CrossrefPubMedGoogle Scholar
  • 98 Güler E, Babur Güler G, Demir GG, Hatipoğlu S. A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?. Anatol J Cardiol 2015; 15 (12) 1020-1029
    CrossrefPubMedGoogle Scholar
  • 99 Kröll D, Stirnimann G, Vogt A. , et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br J Clin Pharmacol 2017; 83 (07) 1466-1475
    CrossrefPubMedGoogle Scholar
  • 100 Kröll D, Nett PC, Borbély YM. , et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. Surg Obes Relat Dis 2018; 14 (12) 1890-1896
    CrossrefPubMedGoogle Scholar
  • 101 Hu YF, Liao JN, Chern CM. , et al. Identification and management of noncompliance in atrial fibrillation patients receiving dabigatran: the role of a drug monitor. Pacing Clin Electrophysiol 2015; 38 (04) 465-471
    CrossrefPubMedGoogle Scholar
  • 102 Keita I, Aubin-Auger I, Lalanne C. , et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence 2017; 11: 1625-1634
    CrossrefPubMedGoogle Scholar
  • 103 Ombandza-Moussa E, Samama MM, Horellou MH, Chatelier AL, Elalamy I, Conard J. Influence of oral anticoagulant treatment on D-dimers levels [in French]. Ann Biol Clin (Paris) 2001; 59 (05) 579-583
    PubMedGoogle Scholar
  • 104 van Ryn J, Stangier J, Haertter S. , et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (06) 1116-1127
    Article in Thieme ConnectPubMedGoogle Scholar
  • 105 Xarelto: summary of product characteristics [Internet]. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf . Accessed March 5, 2019
    PubMedGoogle Scholar
  • 106 Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors. Clin Appl Thromb Hemost 2016; 22 (05) 423-428
    CrossrefPubMedGoogle Scholar
  • 107 Verhamme P, Wells PS, Segers A. , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 2016; 116 (04) 747-753
    Article in Thieme ConnectPubMedGoogle Scholar
  • 108 Liesenfeld KH, Lehr T, Dansirikul C. , et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9 (11) 2168-2175
    CrossrefPubMedGoogle Scholar
  • 109 Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 01) 9S-16S
    CrossrefPubMedGoogle Scholar
  • 110 Information professionnelle du Compendium Suisse des Médicaments: Xarelto [Internet]. Compendium Suisse des Médicaments; 2018 . Available at: https://compendium.ch/mpro/mnr/20753/html/fr?Platform=Desktop#7600 . Accessed February 25, 2019
    PubMedGoogle Scholar
  • 111 Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012; 26 (01) 27-32
    CrossrefPubMedGoogle Scholar
  • 112 Information professionnelle du Compendium Suisse des Médicaments: Eliquis [Internet]. Compendium Suisse des Médicaments; 2019 . Available at: https://compendium.ch/mpro/mnr/22732/html/fr#7300 . Accessed March 19, 2019
    PubMedGoogle Scholar
  • 113 Kubisz P, Stanciakova L, Dobrotova M, Samos M, Mokan M, Stasko J. Apixaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 2017; 18 (07) 609-621
    PubMedGoogle Scholar
  • 114 Lixiana: summary of product characteristics [Internet]. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf . Accessed March 19, 2019
    PubMedGoogle Scholar
  • 115 Information professionnelle du Compendium Suisse des Médicaments: Lixiana [Internet]. Compendium Suisse des Médicaments; 2017 . Available at: https://compendium.ch/mpro/mnr/26503/html/fr#7300 . Accessed March 19, 2019
    PubMedGoogle Scholar
  • 116 Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 2016; 55 (06) 641-655
    CrossrefPubMedGoogle Scholar
  • 117 Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012; 40 (12) 2250-2255
    CrossrefPubMedGoogle Scholar
  • 118 Gosselin RC, Adcock DM, Bates SM. , et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
    Article in Thieme ConnectPubMedGoogle Scholar
  • 119 Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 2015; 39 (03) 288-294
    CrossrefPubMedGoogle Scholar
  • 120 Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016; 172 (03) 315-336
    CrossrefPubMedGoogle Scholar
  • 121 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
    CrossrefPubMedGoogle Scholar
  • 122 Douxfils J, Ageno W, Samama C-M. , et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16 (02) 209-219
    CrossrefPubMedGoogle Scholar
  • 123 Erdoes G, Martinez Lopez De Arroyabe B, Bolliger D. , et al. International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery. Anaesthesia 2018; 73 (12) 1535-1545
    CrossrefPubMedGoogle Scholar
  • 124 Steiner T, Böhm M, Dichgans M. , et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102 (06) 399-412
    CrossrefPubMedGoogle Scholar
  • 125 Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76 (03) 455-466
    CrossrefPubMedGoogle Scholar
  • 126 Mendell J, Zahir H, Matsushima N. , et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13 (05) 331-342
    CrossrefPubMedGoogle Scholar
  • 127 Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol 2018; 132: 169-179
    CrossrefPubMedGoogle Scholar